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We studied longitudinally inﬂammatory reactions and serum C-reactive protein (S-CRP) levels in 52 colorectal cancer patients
treated with a median of six 3-weekly cycles of raltitrexed 1.5–3.0 mg m
72 combined with oral carmofur (1-hexylcarbomoyl-
5-ﬂuorouracil) 300–400 mg m
72 on cycle days 2–14. Thirty-nine (75%) of these patients had fever on days 2 to 9 after
receiving raltitrexed, 49 (94%) had fatigue Gr.51, and 49 (94%) elevated S-CRP without a documented infection. The
systemic inﬂammatory composite score (consists of body temperature, fatigue, S-CRP, interleukin-6 (S-IL-6), S-IL-8, and
tumour necrosis factor-a (S-TNFa) levels) was calculated in a cross-sectional one-cycle study involving 60 colorectal cancer
patients treated with single-agent raltitrexed, raltitrexed and carmofur, or 5-ﬂuorouracil-based chemotherapy (n=20 in each
group). The median S-CRP, S-IL-6, and S-TNFa levels were higher 7 days after giving raltitrexed (57 vs 23 mg l
71,6 4vs
10 ng l
71, and 11 vs 10 ng l
71, respectively) or raltitrexed+carmofur (142 vs 10 mg l
71,6 4vs 10 ng l
71, and 16 vs 9n gl
71,
respectively) than at baseline (P50.01 for each comparison), but not when 5-ﬂuorouracil-based regimens were administered.
These ﬁndings suggest that colorectal cancer patients treated with raltitrexed may develop drug-related systemic inﬂammation,
which may be difﬁcult to discriminate from infection.
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Raltitrexed (Tomudex
1), designed as a speciﬁc thymidylate
synthase inhibitor, has shown comparable efﬁcacy to the combina-
tion of bolus 5-ﬂuorouracil (5-FU) and leucovorin in the treatment
of metastatic colorectal cancer (Cocconi et al, 1998; Cunningham
et al, 1996; Pazdur and Vincent, 1997). However, the toxicity
proﬁle is dependent on the regimen (Cunningham et al, 1996;
Garcia-Vargas et al, 1999; Pazdur and Vincent, 1997), and, in
general, raltitrexed causes less leukopenia and mucosal injury than
5-FU combined with leucovorin, but more fatigue, fever and tran-
sient increases in the hepatic transaminase levels.
Raltitrexed has been extensively investigated as a single drug,
and its use in combination therapies is currently under clinical
evaluation. We have recently studied the combination of ralti-
trexed and carmofur (1-hexylcarbomoyl-5-FU), an orally
administered 5-FU derivate that is metabolised to FdUMP and
acts as intravenous 5-FU (Miyauchi et al, 2000), as the ﬁrst-line
treatment of colorectal carcinoma. This combination has a
promising 50% response rate in ﬁrst line when raltitrexed is given
1.5 to 3.0 mg m
72 on day 1 and carmofur 300 to 400 mg m
72
on days 2 to 14 of a 3-week cycle (Osterlund et al, 2001). Many
of the patients treated with this combination or with single-agent
raltitrexed presented with high spiking fever and fatigue within
72 h of raltitrexed infusion, followed by an increase in the serum
C-reactive protein (CRP) level, while the blood neutrophil counts
remained virtually unaltered. Despite extensive clinical and
imaging examinations, presence of infection could not be veriﬁed
in these patients. Recovery was invariably complete within one
week irrespective of the type of treatment given (broad spectrum
antibiotics or oral oﬂoxacin), or whether symptomatic care only
without antibiotics was given. Similar symptoms typically recurred
following further raltitrexed infusions in the same patients, which
also suggested the presence of non-infectious, systemic inﬂamma-
tion.
The triad of fever, fatigue, and an increased serum CRP level
is typical of systemic inﬂammation. The most common cause of
systemic inﬂammation is infection (Anonymous, 1992; Bone,
1996), but since no evidence for recurring infections was
obtained in our patients and antimicrobial therapy appeared to
have no effect on the outcome, we assumed that the treatment
itself might trigger a systemic inﬂammatory reaction in these
patients. To evaluate this hypothesis we carried out two prospec-
tive studies, one longitudinal and one cross-sectional study,
which are reported here. In the longitudinal study the frequency
of fever, fatigue, and an increased serum CRP level were inves-
tigated in patients who were treated with the combination of
raltitrexed and carmofur for metastatic colorectal cancer, and
the responsiveness of the symptoms to dexamethasone. In the
one-cycle cross-sectional study, the severity of systemic inﬂam-
mation during one cycle of treatment was compared between
patients treated either with single-agent raltitrexed, the combina-
tion of raltitrexed and carmofur, or a 5-FU-based regimen. In
the cross-sectional study we measured body temperature, the
degree of fatigue, and the serum levels of CRP, TNF-a, IL-6,
and IL-8 as markers of systemic inﬂammation. Based on these
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www.bjcancer.comanalyses we calculated the systemic inﬂammation composite score
(SICS) to evaluate the severity of inﬂammation in individual
patients (Takala et al, 1999).
PATIENTS AND METHODS
Patients
The protocols of the longitudinal and cross-sectional studies
were approved by the local Ethical Review Board and the
National Agency for Medicines, Helsinki, Finland, and an
informed consent was required from all patients. Both studies
were open and non-randomised. Patients were eligible for inclu-
sion if they were older than 18 (and younger than 75 in the
longitudinal study); had histologically conﬁrmed metastatic or
locally advanced inoperable colorectal cancer; the World Health
Organisation (WHO) performance status 42; and had adequate
bone marrow, renal, and liver functions at initiation of treat-
ment. Exclusion criteria included the presence of other
invasive cancer, with the exception of adequately treated carci-
noma in situ of the cervix and non-melanoma skin cancer;
metabolic, neurological, or psychiatric disease that was incompa-
tible with chemotherapy; a history of serious thromboembolic
event currently under treatment; pregnancy, lactation, or absence
of adequate contraception in fertile patients; and in the cross-
sectional study infection between days 0 and 9 of the treatment
cycle.
The longitudinal study comprised of 52 patients treated with
240 cycles of raltitrexed and carmofur. The study included all
patients who participated in a single institution phase I/II study
investigating the dose and efﬁcacy of the combination of raltitrexed
and carmofur at the Helsinki University Central Hospital between
March 1998 and November 1999 as reported earlier (Osterlund et
al, 2000, 2001). The patient characteristics are shown in Table 1.
The cross-sectional one-cycle study comprised of 60 consecutive
patients with metastatic colorectal cancer treated at the Helsinki
University Central Hospital (Table 1). The patients were treated
with one of three different chemotherapies. Twenty patients were
treated with raltitrexed and carmofur (they also participated in
the longitudinal study); 20 patients received raltitrexed as a
single-agent therapy; and 20 patients received 5-FU in combination
with leucovorin (either the Mayo 5-day bolus injection regimen or
the de Gramont regimen were used), or single-agent carmofur. The
three treatment arms were balanced with respect of gender, age,
disease sites, and prior treatments (Table 1).
Chemotherapy regimens
Raltitrexed 3.0 mg m
72 was given as a 15 to 30 min infusion 3-
weekly, the starting day of the next cycle was day 22. When given
in combination with carmofur, raltitrexed 1.5 to 3.0 mg m
72 was
administered on the cycle day 1 and carmofur 300 to
400 mg m
72 orally divided in three daily doses on cycle days
2–14, followed by a week of rest (Osterlund et al, 2001). The
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Table 1 Patient characteristics
Longitudinal study Cross-sectional study
Raltitrexed+ Raltitrexed+
Feature Carmofur Carmofur Raltitrexed 5-FU-based
No. entered 52 20 20 20
Gender, male : female 26 : 26 9 : 11 12 : 8 10 : 10
Median age (range), years 61 (41–75) 61 (48–73) 65 (40–77) 63 (45–77)
Cancer, Rectum : Colon 30 : 22 15 : 5 9 : 11 7 : 13
Prior treatment:
Chemonaive 30 12 10 12
Adjuvant chemotherapy 8 4 5 4
Palliative chemotherapy 14 4 5 4
No. of metastatic sites
1 19 5 10 11
22 5 1 0 7 6
3+ 8 5 3 3
No. with metastases in
Liver 43 16 14 14
Lung 31 16 11 6
Other 17 8 6 10
No. of cycles given, median (range)
3-weekly 6 (1–17) 2.5 (1–7) 1 (1–10)
adjusted to 3-weekly 1 (1–10)
5-ﬂuorouracil based treatment regimen
Bolus Mayo 5
Continuous de Gramont 7
Oral Carmofur 8
Performance status, day 0
0 or 1 40 15 12 18
2 or 3 12 5 8 2
Infection and antibiotics 9 2 2 3*
Dexamethasone used
To prevent fever and fatigue 6
As an antiemetic 0 1 1
*One patient was excluded from analyses due to infection.
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20 mg m
72 and 5-ﬂuorouracil 425 mg m
72 on days 1 to 5 of the
cycle, repeated every four weeks. The ‘simpliﬁed de Gramont’
regimen was given every 2 weeks with leucovorin 400 mg m
72
as a 2-h infusion followed by 5-ﬂuorouracil 400 mg m
72 given
as a bolus, followed by a continuous infusion of 5-ﬂuorouracil
3.0 to 3.6 g m
72 48 h using a portable pump. Single-agent
carmofur was administered as 3-week cycles, where carmofur
300 mg m
72, divided in three daily doses, was ﬁrst given orally
for 14 days, followed by 1 week of rest. The number of cycles
was not limited in the longitudinal study, and the combination
of raltitrexed and carmofur was given until disease progression
or dose-limiting toxicity was encountered.
Clinical evaluation
At study entry physical examination was performed, the perfor-
mance status evaluated, and the European Organization for
Research and Treatment of Cancer (EORTC) quality of life ques-
tionnaire (QLQ) C-30 forms were ﬁlled. At the end of each cycle
physical examination, the performance status, and treatment toxi-
cities using the National Cancer Institute of Canada toxicity
Criteria were assessed. In the longitudinal study body tempera-
ture was measured at least daily during the ﬁrst days of the
cycle and whenever fever was suspected. In the cross-sectional
study, body temperature was measured at least every morning,
QLQ was assessed once weekly, and patients kept a diary of
side-effects and of general well-being. Response to treatment
was assessed according to the World Health Organization
(WHO).
Special attention was paid to infection diagnostics of febrile
patients. In addition to careful clinical examinations, urine and
blood samples were collected repeatedly for bacterial and fungal
culture, antigen tests, and microbial serology. Conventional radi-
ological imaging, ultrasound, or computed tomography were
used to ﬁnd infection foci.
In the longitudinal study, all infectious episodes started on cycle
days 10 to14 at the time of the leukocyte nadir, or later than this
during the treatment cycle. Four patients were diagnosed with
infection (urinary tract infection, n=1; biliary stent sepsis, n=1;
pneumonia, n=1; erysipelas, n=1). In addition, ﬁve patients had
a suspected infection with concurrent Gr. 3 or 4 neutropenia
and diarrhoea.
In the cross-sectional study, seven patients developed infection
or suspected infection during the study cycle and were treated with
antibiotics. Pneumonia occurred in one patient, enteritis of
unknown origin in one, urinary tract infection in three, and urin-
ary tract infection was suspected in two patients. One of the
urinary tract infections was a septic urinary catheter infection
and started already on day 4 of the cycle, whereas the other infec-
tious episodes began on cycle days 11 to 21, i.e. after the blood
samples for the laboratory tests for the presence of systemic inﬂam-
mation had been collected.
Laboratory tests
Blood haemoglobin, the white blood cell and leukocyte differential
counts, the platelet count, and the erythrocyte sedimentation rate
(ESR) were measured, as well as serum CRP, alkaline phosphatase,
alanine aminotransferase (SGPT), aspartate aminotransferase
(SGOT), bilirubin, creatinine, Na, K, and calcium levels at the
study entry prior to the ﬁrst chemotherapy infusion. In the long-
itudinal study these tests were repeated on day 7 or 8 of the
cycle, and immediately prior to the next cycle. The blood tests were
repeated every second day if grade IV cytopenia was present. In the
cross-sectional study, these tests were done thrice during each
chemotherapy cycle (on cycle day 6 to 8 and 12 to 15, and before
starting the next cycle).
Immulite (Diagnostic Products, Los Angeles, CA, USA) chemilu-
minescence analysis was used to measure the serum levels of TNF-a
(the detection limit, 1.7 ng l
71), IL-6, and IL-8 (the detection
limit, 5 ng l
71 for each) as described previously (Takala et al,
2000). The cytokine levels were determined in the cross-sectional
study at the study entry, and once on days 6 to 8, 12 to 15, and
at the end of the cycle. The serum cytokines levels could be
measured on the four planned times in 59 patients, and three times
in one case. An insufﬁcient amount of plasma was obtained in one
case on the day 7 sample, and only two of the cytokines could be
analysed.
Evaluation of systemic inﬂammation
To evaluate the severity of systemic inﬂammation we determined
the systemic inﬂammation composite score (SICS) (Takala et al,
1999). To obtain the SICS, a subscore (grade) was ﬁrst assigned
to the body temperature (graded from 0 to 4), fatigue (from 0
to 3), and the serum levels of CRP, TNF-a, IL-6, IL-8 (each graded
from 0 to 4, Table 2). The maximum obtainable SICS was thus
564+1 63, i.e. 23, where a high score denotes the presence of
severe systemic inﬂammation. The severity of systemic inﬂamma-
tion was assigned for the 60 patients who participated in the
cross-sectional study four times; once before the cycle, and on cycle
days 6 to 8, 12 to 15, and at the end of the cycle.
Study endpoints and statistical methods
In the longitudinal study, nine treatment cycles were excluded from
analysis due to the presence of a diagnosed infection and subse-
quent antimicrobial therapy. Six patients in the longitudinal
study were treated with intravenous and/or oral dexamethasone
during a total of 17 treatment cycles to diminish symptoms related
to systemic inﬂammation (see below). Data from these 17 cycles
were also excluded from the main analyses. Repeated measures
ANOVA statistics was used to examine changes in variables over
time.
In the cross-sectional study the SICS score could not be calcu-
lated in three patients; in two patients due to a missing value
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Table 2 Grading of the SICS subscores
Characteristic Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Fever, 8C* 537.1 37.1–38.0 38.1–40.0 >40, 524 h >40, 424 h
Fatigue* No change fall of 1 unit in the fall of 2 units fall of 3 units –
WHO performance status
CRP, ng l
71** 510 10–50 51–100 101–200 4200
IL-6, ng l
71** 510 10–50 51–150 151–300 4300
IL-8, ng l
71** 510 10–50 51–150 151–300 4300
TNFa,n gl
71** 510 10–25 26–50 51–100 4100
*According to National Cancer Institute of Canada common toxicity criteria. **Modiﬁed from Takala et al, 1999
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and in one case due to the presence of infection (the 5-FU group).
The Mann–Whitney U-test or the Kruskall–Wallis test were used
to compare groups for the difference between the day 0 (the base-
line value before staring treatment) and day 7 (Dday 0 to 7) values,
and the Wilcoxon signed rank test for paired comparisons. The
SICS analysis was done with and without the six patients who
had an infectious episode and the two patients who received a
single dose of 10 mg intravenous dexamethasone prior to
chemotherapy as an antiemetic (Table 1). All statistical signiﬁcance
tests are two-tailed at the 5% level. Bonferroni correction for
multiple comparisons was used when appropriate.
RESULTS
The longitudinal study
Body temperature, fatigue, and serum CRP during raltitrexed and
carmofur treatment Fever and/or fatigue occurred during 161
(75%) of the 214 cycles given to 52 patients (fever 437.08C,
n=39; 438.08C, n=24). Fatigue grade 51 was present in 49
(94%) patients, and other commonly recorded symptoms included
anorexia with slight nausea, and ﬂu-like symptoms with headache
and myalgia. Serum CRP level increased more than 10 mg l
71 in
49 (94%) and the ESR more than 10 mm h
71 in 45 (87%)
patients.
Body temperature followed a characteristic pattern, peaking 2 to
4 days after raltitrexed administration, and resolving usually within
4 days thereafter (range, 1 to 7 days). A rise in body temperature
was accompanied with a rise in the serum CRP level and the blood
ESR, which reached the maximum values on about cycle days 7 to
8, and then returned to the precycle levels by the ﬁrst day of the
next cycle. The frequency of fever (P=0.0085) and elevation of
serum CRP (P=0.0014) increased over the ﬁrst three cycles of
carmofur plus raltitrexed treatment, whereas no marked change
took place in the mean blood neutrophil levels (P=0.25, Figure
1). No signiﬁcant change in the median baseline (precycle) serum
CRP levels was found during the ﬁrst six cycles of carmofur and
raltitrexed treatment (P=0.27). One of the four patients treated
at raltitrexed dose levels 1.5 or 2.0 mg m
72, and eight of the 16
patients treated at dose levels 2.5 or 3.0 mg m
72 developed dose
limiting symptoms or signs suggestive of systemic inﬂammatory
reaction (P=0.59, Fisher’s exact test).
Effect of dexamethasone Six patients treated with the combina-
tion of carmofur and raltitrexed and who suffered from recurring
post-infusion fever and fatigue, were given dexamethasone in an
attempt to prevent the post-infusion systemic inﬂammatory reac-
tion. A single dose of 10 mg intravenous dexamethasone given at
the time of raltitrexed infusion failed to prevent the symptoms,
but when 4.5 mg of dexamethasone t.i.d. was added to the regimen
and when this dose was tapered down over 10 days, neither fever,
fatigue, the ﬂu-like symptoms nor elevations of CRP and ESR
recurred during the subsequent chemotherapy cycles in all patients.
Interestingly, ﬁve of the six patients evaluable for treatment
response progressed after starting dexamethasone for prevention
of the symptoms.
The cross-sectional study
Body temperature, fatigue, serum CRP level and the blood
neutrophil counts The changes in the serum CRP level, body
temperature, and the blood neutrophil counts during one cycle
of chemotherapy consisting either of raltitrexed plus carmofur,
single-agent raltitrexed, or a 5-FU based regimen are shown in
Figure 2 (n=59). The post-infusion elevations of serum CRP and
body temperature were highly signiﬁcant as compared to the
precycle values (P=0.0001 and 50.0001, respectively). The serum
CRP level and the body temperature peaked on the cycle day 7
in patients treated with either carmofur+raltitrexed or single-agent
raltitrexed (repeated measures analysis of variance P=0.021 and
0.084, respectively), but no such elevations were observed in
patients who received 5-FU based chemotherapy. Grade 3 or 4
neutropenia was found only in four (7%) of the 59 patients during
the chemotherapy cycle with no statistically signiﬁcant difference
between the treatment groups (P=0.89), and no signiﬁcant changes
in the blood neutrophil counts took place during the cycle (P=0.53,
Figure 2).
Elevated body temperature (range, from 37.0 to 40.18C)
occurred more frequently in patients who received single-agent
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Figure 1 The serum C-reactive protein (CRP) level, presence of fever (graded as in Table 2), and the blood neutrophil count in the longitudinal study.
The mean and 95%CI of the 231 cycles given to 52 patients are indicated by bars.
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with 5-FU based regimens (n=11 vs 11 vs 1, P=0.0091). The
median body temperature was higher on cycle day 7 (37.38C,
37.58C and 36.48C, respectively) as compared with the baseline
(36.3 to 36.58C) in patients treated with the raltitrexed-containing
regimens (P=0.0001). Patients with fever had also fatigue and
usually ﬂu-like symptoms (anorexia, myalgia, and headache). The
fatigue grade was lower in patients treated with the 5-FU based
regimens than in those who received raltitrexed-based therapy
(median, 0 vs 1 vs 1, P50.0001), and the increase in fatigue was
also greater in the raltitrexed arms than in the 5-FU based therapy
arm based on the quality-of-life questionnaires. The treating physi-
cian-estimated degree of fatigue and the patient-reported fatigue
based on the QLQs showed strong correlation (Spearman rank
correlation coefﬁcient 70.632, P50.001). As in the longitudinal
study, the changes in the body temperature and fatigue were smal-
ler during the ﬁrst chemotherapy cycle as compared to the later
cycles (Figure 3).
Markers of systemic inﬂammation The median serum CRP, IL-
6, IL-8, and TNFa levels were higher 7 days after starting ralti-
trexed and carmofur therapy as compared to the precycle levels
(142 vs 10 mg l
71 64 vs 10 ng l
71,2 1vs 11 ng l
71, and 16 vs
9n gl
71, respectively, P50.001 for each comparison). Similarly,
the median serum levels of CRP, IL-6, and TNFa were signiﬁcantly
higher on the cycle day 7 as compared with the precycle levels after
commencing single-agent raltitrexed (57 vs 23 mg l
71,6 4vs
10 ng l
71, and 11 vs 10 ng l
71, respectively, P50.01 for each
comparison), but no similar effect was found for IL-8 (22 vs
21 ng l
71). In contrast, patients treated with the 5-FU-based regi-
mens had unchanged serum levels of CRP (6 vs 7m gl
71), IL-6 (9
vs 7n gl
71), TNFa (9 vs 9n gl
71), and IL-8 (7 vs 7n gl
71). The
increases in the serum cytokine levels were more marked in
patients who had received more than one cycle of raltitrexed-
containing therapies than in those who were assessed during the
ﬁrst chemotherapy cycle (Figure 4).
The systemic inﬂammatory composite score (SICS) When the
systemic inﬂammatory composite score was calculated both at the
baseline (before giving chemotherapy infusion) and on day 7 of
the chemotherapy cycle, the score increased markedly in patients
who received raltitrexed (P50.0001). The median cycle day 7
score was higher than the precycle score in patients treated with
either raltitrexed and carmofur (9.5 vs 2.5, P=0.0003) or single-
agent raltitrexed (6 vs 3, P=0.0004), whereas in patients given 5-
FU based regimens the score remained unaltered (1.5 vs 1.5).
The increase in the score was smaller in patients who were assessed
during the ﬁrst chemotherapy cycle as compared with those
assessed during the later cycles (P=0.027, Figure 5). Raltitrexed-
treated patients had signiﬁcantly higher cycle day 7 scores irrespec-
tive of whether only the patients assessed during the ﬁrst cycle or
those assessed during the later cycles were included in the analysis.
The results remained essentially unchanged when patients with a
documented infection during the cycle (n=6) and those who
received dexamethasone as an antiemetic (n=2) were excluded
(in the raltitrexed plus carmofur group the median day 7 SICS
was 8.5 vs 2.5 at baseline, P=0.0006; in the single-agent raltitrexed
group 6 vs 2.5, P=0.0007; and in the 5-FU based chemotherapy
group 1.0 vs 1.0). Gender, age at diagnosis, the WHO performance
score, the number and extent of liver metastases were not signiﬁ-
cantly associated with the frequency of systemic inﬂammatory
reaction.
DISCUSSION
The rapid onset of spiking fever, fatigue, ﬂu-like symptoms, and
the increases in the serum CRP and inﬂammatory cytokine levels
suggest that the patients treated with the combination of raltitrexed
and carmofur or with single-agent raltitrexed developed a systemic
inﬂammatory reaction a few days following chemotherapy infu-
sions. Several lines of evidence suggest that the symptoms were
not triggered by undiagnosed microbial infections, but that the
major cause of symptoms was drug-related systemic inﬂammation.
First, we failed to ﬁnd evidence for the presence of microbial infec-
tion in the majority of patients despite extensive and repeated
clinical examinations. Second, treatment with antibiotics appeared
to have little effect on the clinical symptoms or the CRP levels.
Third, the patients did not have neutropenia, an important risk
factor for acute infection, on the days preceding the symptoms.
The leukocyte nadir occurred on cycle days 10 to 14 after the ralti-
trexed infusion, whereas fever was usually present earlier, starting
on the cycle days 2 to 4 days and resolving in all cases by the cycle
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Figure 2 The serum CRP level, body temperature, and the blood neu-
trophil count as assessed during one cycle of chemotherapy in 59 patients
treated with three different chemotherapies (the cross-sectional study).
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after the day 7 of the cycle. Fourth, in most patients fever, fatigue,
and the serum CRP elevations recurred following every chemother-
apy cycle, which is not suggestive of infection-related fever, and the
symptoms and CRP elevations were limited to patients who
received raltitrexed. Taken together, although the presence of infec-
tion cannot be excluded with certainty as a cause of the symptoms,
the present ﬁndings suggest that the symptoms and the related
serum chemistry changes were caused by a treatment-related
systemic inﬂammatory reaction.
The severity of the systemic inﬂammation, as deﬁned by the
systemic inﬂammatory composite score, appeared to increase with
the increasing duration of raltitrexed treatment, and, in general, the
combination of raltitrexed and carmofur caused more severe symp-
toms than raltitrexed alone. The symptoms and the concomitant
elevations in the serum CRP and cytokine levels did not occur in
patients treated with the 5-FU based regimens. Systemic inﬂamma-
tion that is not triggered by infection is apparently unusual in
colorectal cancer patients treated with chemotherapy regimens
consisting of 5-FU, oxaliplatin, or irinotecan (Andre et al,
1999a,b; Bleiberg and de Gramont, 1998; de Gramont et al, 1997;
Saltz et al, 2000). However, similar symptoms have been observed
in patients receiving bleomycin or cytarabine, which may induce
inﬂammatory cytokine production (Chiche et al, 1993; Mishra et
al, 2000; Sleijfer et al, 1998). The toxicities found in the present
raltitrexed-based therapies resemble the effects linked to proinﬂam-
matory cytokines, such as IL-6 and TNFa. At present, the
underlying mechanism(s) by which raltitrexed alone or in combi-
nation with carmofur triggers a systemic inﬂammatory reaction
remain unknown.
Recurring fever, fatigue, and elevations of serum CRP could be
inhibited with dexamethasone treatment in all patients tested.
Hypothetically, a systemic inﬂammatory response triggered by
raltitrexed might be beneﬁcial by enhancing the immune defence
against cancer. TNF-a and IL-6, which are pleiotropic cytokines,
may have anti-tumour properties (Gluckman et al, 1997; May et
al, 1988; Tanaka et al, 1997), and may be of beneﬁt as chemother-
apy agents in experimental cancer and even in the clinical
treatment of colorectal cancer (de Vries et al, 1998, 1999; Lindner
et al, 1999; Scheid et al, 1994; Tomita et al, 1998), and might act in
synergy with conventional chemotherapeutics such as 5-FU (Oka et
al, 1997; Watanabe et al, 1988). Increased anti-tumour activity
associated with systemic inﬂammation might in part explain the
as high as 50% response rate obtained by us with the combination
of raltitrexed and carmofur in the treatment of metastatic colorec-
tal cancer as the ﬁrst-line therapy (Osterlund et al, 2001). However,
the effect of dexamethasone on the treatment efﬁcacy remains
unknown and requires further study.
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Figure 3 Body temperature and the fatigue grade of 59 patients who participated in the cross-sectional study. The results are shown split by the type of
treatment given and the chemotherapy cycle assessed (cycle 1, evaluation was carried out during the ﬁrst chemotherapy cycle; cycle 41, evaluation was
done during one of the later cycles). The individual patient values (open circles) and the medians (horizontal lines) are indicated. Day 0 refers to the baseline
(precycle) value, and day 7 is the 7
th day of the chemotherapy cycle.
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Figure 4 Serum levels of CRP, IL-6, IL-8, and TNFa of 59 patients in the cross-sectional study. The symbols and cycles are as in Figure 3.
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partly by genetic factors (Louis et al, 1998). Systemic inﬂamma-
tion may lead to inﬂammation-mediated organ failure (Mira et
al, 1999), and may also trigger a counter-reaction characterised
by the development of immune suppression (Bone, 1996), which
is associated with poor outcome in patients with sepsis (Volk et
al, 1996). Although raltitrexed has a tolerable toxicity proﬁle in
general, the raltitrexed treatment-related mortality rate was
recently found to be unexpectedly high (Anonymous, 1999;
Maughan et al, 1999). Some of the patients with a fatal
outcome had symptoms suggestive of systemic inﬂammation,
and ultimately developed multiorgan failure. Many of the
patients with severe toxicities did not have a proper dose reduc-
tion based on treatment-related neutropenia occurring in
conjunction with diarrhoea or a deteriorating kidney function,
which may have led to accumulation of toxicity (Anonymous,
1999; Maughan et al, 1999). Hence, although a systemic inﬂam-
matory reaction might have theoretical potential beneﬁts by
increasing tumour cell destruction, it might also have detrimen-
tal effects by eliciting toxicity, possibly leading to immune
suppression and organ dysfunction.
We conclude that colorectal carcinoma patients treated with
single-agent raltitrexed or the combination of raltitrexed and
carmofur often develop fever, fatigue and elevation in the serum
CRP and proinﬂammatory cytokine levels, which peak a few days
after raltitrexed infusion and may recur after subsequent cycles.
These features are suggestive for a drug-related systemic inﬂamma-
tion. The symptoms and laboratory ﬁndings may be difﬁcult to
differentiate from those caused by microbial infections. Corticos-
teroids may be effective in prevention of the symptoms, but they
may mask underlying microbial infections, and their inﬂuence on
the treatment efﬁcacy is unknown.
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